Cure GBM: Innovative Approaches to Glioblastoma Treatment

Jane Wakefield shares why she and her brother Richard founded Cure GBM after their father was diagnosed with glioblastoma multiforme (GBM) in 2021.Their dad’s symptoms began in early 2021. After being admitted to hospital in March (initially thought to be a TIA), he had a craniotomy about a week later. The surgery initially went well — but he developed an infection. Despite treatment, he returned from surgery on life support. Jane and Richard lost him five weeks after his operation.A lifelong friend (a neurosurgeon in Scotland) helped them understand GBM and navigate the medical reality. Over time, their conversations led to one conclusion: if they wanted to see change, they needed to build it.In this episode, Jane and Richard explain Cure GBM’s mission: bringing sonodynamic therapy (SDT) forward through trials in Europe, with a focus on speed, safety, and accessibility.Richard describes SDT in simple terms:an existing drug (used in brain surgery to highlight tumour cells) is absorbed by cancer cellsultrasound energy activates itthe reaction occurs inside cancer cellsthe goal is to damage tumour cells without invasive proceduresThey describe their vision for the future: SDT as a gentle, non-invasive outpatient treatment, potentially delivered alongside routine MRI appointments.They also discuss the practical realities of building a company: device access, regulatory requirements, funding, and why they believe a company can move faster than traditional routes.🔗 More info: HERE📱 Socials: search cure.gbm (Instagram / Facebook / LinkedIn)⚠️ Content note: This episode includes bereavement, end-of-life care, glioblastoma, and discussion of experimental/early-stage treatment research.